About humacyte inc - HUMA
Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.
HUMA At a Glance
Humacyte, Inc.
2525 East North Carolina Highway 54
Durham, North Carolina 27713
| Phone | 1-919-313-9633 | Revenue | 2.04M | |
| Industry | Biotechnology | Net Income | -40,833,000.00 | |
| Sector | Health Technology | Employees | 184 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
HUMA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 74.54 |
| Price to Book Ratio | 59.621 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.66 |
| Enterprise Value to Sales | 81.51 |
| Total Debt to Enterprise Value | 0.39 |
HUMA Efficiency
| Revenue/Employee | 11,076.087 |
| Income Per Employee | -221,918.478 |
| Receivables Turnover | 4.621 |
| Total Asset Turnover | 0.016 |
HUMA Liquidity
| Current Ratio | 3.69 |
| Quick Ratio | 2.95 |
| Cash Ratio | 2.756 |
HUMA Profitability
| Gross Margin | -736.457 |
| Operating Margin | -5,271.688 |
| Pretax Margin | -2,003.582 |
| Net Margin | -2,003.582 |
| Return on Assets | -32.122 |
| Return on Equity | N/A |
| Return on Total Capital | -60.088 |
| Return on Invested Capital | -90.407 |
HUMA Capital Structure
| Total Debt to Total Equity | 2,085.751 |
| Total Debt to Total Capital | 95.425 |
| Total Debt to Total Assets | 55.726 |
| Long-Term Debt to Equity | 2,007.655 |
| Long-Term Debt to Total Capital | 91.852 |